Bioversys and GIBF2 Enter Strategic Investment for BV100 Clinical Program in China
Wednesday, 11 September 2024, 00:00
Bioversys Partners with GIBF2 for Investment in BV100 Program
Bioversys has secured a strategic investment of US$ 6 million from GIBF2, aimed at supporting the launch of the BV100 clinical program in China.
Investment Details
- GIBF2's investment will enhance Bioversys' capability to advance its clinical studies.
- The BV100 Phase 1 clinical trial is expected to commence in the first half of 2025.
Global Implications
This investment is a significant step for Bioversys as it prepares for a global clinical initiative following the completion of studies in China.
For more details, please visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.